Clinical trial readout dates for Vaxcyte Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 31 valent pneumococcal conjugate vaccine Pneumococcal Disease · NCT07284654 | September 2026 Primary data collected |
| Phase 2 0.5 mL of the low dose VAX-31 Pneumococcal Vaccines · NCT06720038 | December 2027 Ongoing |
Vaxcyte Inc. reported $2.26B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $297M; at that rate the cash would last about 8 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-04 |